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C
hris tmas  is  a 
time when many 
entirely rational 
people  whose 
views are based 
solidly on empirical evi-
dence the rest of the year 
suspend their critical fac-
ulties and say things they 
know to be untrue. Just in 
case any young children 
have picked up their par-
ents’ copy of the BMJ, we 
won’t go into detail except to 
say that the subject of these 
falsehoods traditionally 
originates in the far north.1 
Such stories are harmless 
and those telling them will, 
when their children reach 
an appropriate age, abandon 
the pretence. Yet other people hold views that 
are equally untrue and do so with an unshake-
able faith, never admitting they are wrong 
however much contradictory evidence they 
are presented with.
Some of these views are harmless, but 
o thers cost lives. It is easy to think of con-
temporary examples. “HIV is not the cause 
of AIDS.”2 “The measles, mumps, and rubella 
vaccine cannot be considered safe.”3 “Second 
hand smoke is simply an irritant and there 
is no conclusive evidence that it is danger-
ous.”4 And, with potentially the greatest 
consequences for our species, “the evidence 
that the world is warming is inconclusive, 
and, if not, the evidence that global warming 
is caused by anthropogenic carbon emissions 
is unproven.”5
Denialism and its history
The term “denialism” has been coined to 
describe this phenomenon. First popular-
ised by the American Hoofnagle brothers, 
one a lawyer and the other a physiologist, 
it involves the use of rhetorical arguments 
to give the appearance of legitimate and 
unresolved debate about matters generally 
considered to be settled.6 The term can be 
traced to people who deny the existence of 
the Holocaust, but it has subsequently been 
applied much more widely. Denialism can 
be recognised by the presence of six key fea-
tures (box).6  7 It is, however, important not to 
confuse denialism with genuine scepticism, 
which is essential for scientific progress. 
Sceptics are willing to change their minds 
when confronted with new evidence; deniers 
are not. Unfortunately, 
confusion is encouraged 
by the liberal use of the 
term, such as when the 
current British govern-
ment uses the term “def-
icit deniers” to attack 
critics of its economic 
policy, a group that now 
includes large num-
bers of distinguished 
economic researchers, 
among them several 
Nobel laureates.8
Although contempo-
rary usage of the term 
is relatively recent, the 
concept of denialism 
has been recognised 
for several decades. A 
chapter entitled “Denial 
of reality” in a 1957 book describing the 
p henomenon of cognitive dissonance notes 
how “. . . groups of scientists have been known 
to continue to believe in certain theories, sup-
porting one another in this belief in spite 
of continual mounting evidence that these 
th eories are incorrect.”9 It highlights, in par-
ticular, the importance of selectivity, whereby 
“one aspect of the process of dissonance reduc-
tion [is] obtaining new cognition which will be 
consonant with existing cognition and avoid-
ing new cognition which will be dissonant 
with existing cognition.” The extent to which 
selectivity influences our views is now widely 
recognised, not least as a result of a best sell-
ing book containing many examples of what is 
termed “confirmation bias.”10 One explanation 
is that confirmation bias is how we deal with 
How the growth of denialism 
undermines public health
Espousing unproved myths and legends is widespread during the festive season,  
but some groups hold views contrary to the available evidence throughout the year.  
This phenomenon, known as denialism, is becoming more elaborate and widespread,  
and poses a danger to public health, say Martin McKee and Pascal Diethelm
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evidence that challenges our 
strongly held beliefs and that 
would otherwise threaten our 
self perceived status as intel-
ligent and moral individuals.
Approaches to denialism
Recent cognitive research, 
some taking advantage of 
advances in brain scanning, 
has shed light on the neuro-
logical processes whereby indi-
viduals interpret a message 
according to who is the mes-
senger. People subconsciously 
suppress recognition of clearly 
contradictory messages from 
politicians that they support, 
yet easily identify contradic-
tions from those they oppose.11 
However, simply ignoring rel-
evant evidence is insufficient. 
Evidence, including authori-
tative corrections, that contra-
dicts strongly held views can, 
paradoxically, reinforce those 
views.12 Thus, research in the 
United States has found that 
registered Republicans who 
are exposed to evidence on the 
importance of social determi-
nants of health are less likely 
to support collective action to 
address them than are those 
not exposed.13
Yet denialism involves more than someone 
accumulating a collection of individual errors 
in information processing. Increasingly, it 
takes on the form of social movements in 
which large numbers of people come together 
and propound their views with missionary 
zeal.14 These views combine exploitation of the 
genuine uncertainty that characterises scien-
tific research with the use of simple falsehood.
Denialists emphasise the limitations of 
st atistical associations for establishing causal-
ity, which are well recognised by aetiological 
epidemiologists, yet ignore other criteria that 
are used to ascertain whether a relationship is 
likely to be causal, such as biological plausibil-
ity, consistency, and strength of association.15 
They may also try to change “the rules of the 
game,” such as in the now notorious example 
when the tobacco industry sponsored efforts 
to define “good epidemiology practice.” The 
initiative would have redefined a relative risk 
of less than two as being not statistically sound 
because of the potential for unrecognised 
confounding and was designed to exclude 
research on the risks associated with passive 
smoking, which typically yield a relative risk 
of 1.3-1.6.16 Other efforts seek to redefine con-
cepts as essentially unresearchable, such as 
in an industry funded report on alcohol that 
stated: “violence is a nebulous concept.”17
Selective use of the scientific literature is 
another approach used by denialists, who 
either promote methodologically flawed 
research that supports their world view over 
more methodologically sound papers or 
undertake intensive searches of papers they 
oppose for anything that might cast doubt on 
the quality of the science. A now notorious 
example is “Amazongate,” in which a report 
by the Intergovernmental Panel on Climate 
Change inappropriately ref-
erenced a statement on a 
report about the sensitivity 
of the rainforest to changes 
in rainfall rather than the 
relevant primary research. 
This inconsequential refer-
encing error, in a report of 
more than 900 pages, was 
then used to undermine the 
entire report.18
Deliberate falsehoods are 
rarely used to convince peo-
ple that something is true, 
but rather are used to seed 
doubt about the actual truth. 
For example, although only 
18% of Americans believe 
that  Pres ident  Barack 
Obama, a church going 
Christian, is a Muslim, an 
additional 43% are unsure.19 
Media commentators don’t 
actually say that that Obama 
is a Muslim, they just say that 
they don’t know whether he 
is or he isn’t, while consist-
ently using the president’s 
full name: “Barack Hussein 
Obama.” In the health arena, 
this approach is commonly 
found in debates about vac-
cines, where denialists play 
on the argument that “you 
can never be sure” when it 
comes to the very small risk of complications 
of vaccinations.
The spread of denialism
Of course, there have always been people who 
have held strong views in the face of over-
whelming evidence to the contrary. Indeed, 
the Flat Earth Society, although a shadow of its 
former self, still exists. However, the world has 
changed in recent decades in three important 
ways, each facilitating the spread of denialism.
The first is the birth of web 2.0, which has 
transformed the internet from a closed pub-
lishing platform into an interactive tool allow-
ing intensive exchange of ideas. People who 
might once have clung on to dissenting views 
in isolation can now locate individuals with 
similar views within seconds. Social media 
enable communities of denialists to grow by 
feeding each other’s feelings of persecution by 
As with vaccines, you can never be sure
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a corrupt elite. This is encouraged by cynicism 
with existing political systems. In one study, 
for example, the people who were most likely 
to believe in 9/11 conspiracy theories were 
those who were disaffected and disengaged 
with the political system.20 Such cynicism is 
growing, a development that should not be 
surprising given how politicians feel able to 
take their countries to war on the basis of dubi-
ous evidence.21
A second issue, in some countries, is the 
espousal of denialism by an increasingly 
partisan media, which expends considerable 
energy identifying supposed conspiracies that 
they then espouse to the general public.22
The third is the growing exploitation of 
the first two issues by corporate interests. 
Although the tobacco industry has been at 
the forefront of such tactics, there are now 
examples from many other sectors, including 
the food and drink, asbestos, oil, and alcohol 
industries. Such activities received consider-
able official support during the administration 
of George W Bush, under whose aegis there 
were widespread attempts to politicise scien-
tific research and advice.23 24 
Tackling denialism
So how should scientists respond to denial-
ism? The first step is to recognise when it is 
present. Denialism changes the rules of the 
game. Conventional approaches to scientific 
progress—such as hypothesis generation and 
testing, and argument and counterargu-
ment—that seek to elicit the underlying truth 
no longer apply.
In some cases, nothing can or needs to be 
done. The persisting belief among many people 
that Princess Diana may have been murdered 
by the security services (32% of the British 
public in one poll),25 26 for example, has ena-
bled some tabloid news papers to fill many 
pages and has wasted much police time, but 
has no persisting implications for public policy.
In other areas, especially where the views 
reflect longstanding cultural beliefs, it may be 
necessary to accept that these views exist and 
adapt messages to take account of them when 
developing policies and practices. Examples 
include the development of health promotion 
campaigns to prevent the spread of HIV27 or to 
encourage the uptake of immunisation.28 Such 
campaigns are based on a detailed assessment 
of the beliefs that would undermine them if not 
confronted. For example, early programmes to 
tackle HIV/AIDS in east Africa had to address 
concerns that promotion of condoms was a 
covert attempt to control the population. It 
may be necessary to accept that there are some 
people who cannot be convinced, but there 
will be many who can.
This leaves those cases where denialist 
views are being promulgated actively by pow-
erful vested interests. Here, we argue, health 
professionals have a responsibility to con-
front the denialists, exposing the tactics they 
use and the flaws in their arguments to a wide 
audience. Again, the first step is recognition. 
When a seemingly bizarre story appears in the 
media that risks undermining public health, 
health professionals should ask: “why is this 
story appearing now?” Many will, however, 
find this approach uncomfortable because it 
conflicts with the common tendency to seek 
compromise and avoid conflict. 
Confronting denialism may also require the 
use of less usual methods of communication, 
such as analogy and narrative. Crucially, it 
demands speed of response. However, health 
authorities and non-governmental organisa-
tions are rarely able to respond rapidly, espe-
cially at weekends when, in our experience, 
misleading stories tend to appear in the media. 
Equally, editors of medical journals (with a few 
exceptions) often seem unable to appreciate 
the need to counter denialist stories.
In this paper we have looked at some of 
the most outrageous examples of denialism. 
Yet denialism is often much more subtle, and 
researchers are far from immune to its effects. 
There is a wealth of evidence on how reviewers 
find real or imagined flaws in papers whose 
messages they disagree with while discounting 
real errors in those they agree with. Perhaps, 
during the Christmas break, we, as reviewers 
and editors, might all take some time out to 
reflect on our own innate cognitive biases as 
well as how to overcome those of others.29
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CHARACTERISTICS OF DENIALISM
Identification of conspiracies: Denialists argue 
that scientific consensus arises not as a result 
of independent researchers converging on the 
same view but instead because researchers 
have engaged in a complex and secretive 
conspiracy. They are depicted as using the 
peer review process to suppress dissent rather 
than fulfil its legitimate role of excluding work 
that is devoid of evidence or logical thought. 
Use of fake experts: It is rarely difficult to find 
individuals who purport to be experts on some 
topic but whose views are entirely inconsistent 
with established knowledge. The tobacco 
industry coined the term “Whitecoats” for 
those scientists who were willing to advance 
its policies regardless of the growing scientific 
evidence on the harms of smoking 
Selectivity of citation: Any paper, no matter 
how methodologically flawed, that challenges 
the dominant consensus is promoted 
extensively by denialists, whereas any minor 
weaknesses in papers that support the 
dominant position are highlighted and used to 
discredit their messages. 
Creation of impossible expectations of 
research: This may involve corporate bodies 
sponsoring methodological workshops that 
espouse standards in research that are so high 
as to be unattainable in practice.
Misrepresentation and logical fallacies: An 
extreme example of this characteristic is 
the phenomenon of reductio ad hitlerum, 
in which anything that Hitler supported 
(especially restrictions on tobacco) is 
tainted by association. Other methods 
of misrepresentation include using “red 
herrings” (deliberate attempts to divert 
attention from what is important), “straw 
men” (misrepresentation of an opposing 
view so as to make it easier to attack), false 
analogies (for example, because both a watch 
and the universe are extremely complex, 
the universe must have been made by some 
cosmic watchmaker), and excluded middle 
fallacies (in which the “correct” answer is 
presented as one of two extremes, with no 
middle way. Thus, passive smoking causes 
either all forms of cancer or none, and as it 
can be shown not to cause some it must, it is 
argued, cause none). 
Manufacture of doubt: Denialists highlight 
any scientific disagreement (whether real or 
imagined) as evidence that the entire topic is 
contested, and argue that it is thus premature 
to take action.
When a seemingly bizarre story appears in the media that risks undermining public 
health, health professionals should ask: “why is this story appearing now?”
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t is a common, and rarely unsuccessful, 
ploy to change the name of something 
unpleasant in order to give it greater 
acceptability. However, changing the name 
of Windscale nuclear plant to Sellafield 
after an accident in 1981 made it no less radio-
active, and the new name quickly acquires all 
the connotations of the old.
Increasing concern has been expressed about 
the presence of complementary and alternative 
medicine (CAM) on the NHS. For instance, the 
House of Commons Science and Technology 
Committee recently reported critically on the 
evidence base for the use of homoeopathy in the 
NHS.1 Nationally and internationally, there has 
been a move to disguise the nature of CAM by 
renaming it “integrative medicine.”2 3 Of course, 
it is something of an insult to medical practition-
ers to suggest that they do not take into account 
their patients’ individuality, autonomy, and 
views as part of their daily practice. It is certainly 
a key tenet of evidence based medicine4 and to 
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Integrative medicine  
and the point of credulity
So called integrative medicine should not be used as a way of smuggling alternative practices 
into rational medicine by way of lowered standards of critical thinking. Failure to detect an 
obvious hoax is not an encouraging sign
suggest that so called integrative medicine is 
somehow confined to the alternative world is a 
canard.
It is sometimes possible to test the status of a 
notion (the terms hypothesis and theory should 
be reserved for ideas that are related to at least 
some form of evidence) by a process of oppo-
sition. This involves testing the status of the 
notion by looking at the limits to which it can 
be pushed.5 Furthermore, there is an excellent 
tradition of testing research areas of dubious 
authenticity by means of a hoax. In 1996, Alan 
Sokal had a paper accepted in a cultural stud-
ies journal, in which he parodied postmodern 
philosophy and cultural studies by making a 
series of exaggerated, wrong, and meaningless 
statements about the potential progressive or lib-
eratory epistemology of quantum physics in the 
style of the field.5 This he subsequently described 
in a book, bluntly called Intellectual Impostures.6 
In the spirit of Sokal, therefore, I responded to 
a mass circulated email invitation to submit a 
paper to something called “The Jerusalem Con-
ference on Integrative Medicine.” 
The invitation announced:
An International Conference on Integrative 
Medicine will be held in October 2010 in 
Jerusalem. It will be a meeting of professionals in 
the field of medicine from around the world that 
will deal with ways to unite the scientific principles 
of modern medicine with the holistic principles of 
alternative medicine…. The scientific committee 
of the convention is still open to accept additional 
topics to the conference program.
On 1 June 2010, I sent them the following 
invented nonsense:
I write to ask if you would be interested in a 
presentation on my recent work on integrative 
medicine. I am an embryologist by background, 
with an extensive publication record, in journals 
including Nature and the Proceedings of the Royal 
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in order to define the best methods of treatment. 
In the presentation, anonymised case histories, 
“testimonies” and positive outcomes will be 
presented. The methodology does not lend itself 
to randomised double blind controlled trials, for 
obvious reasons.
Obviously, the involvement of a sensitive area of 
the body poses special challenges. Ethical practice 
is of significant concern. Informed consent must 
be obtained from all patients in writing, before 
either therapeutic or diagnostic procedures 
are commenced. Although exposure of 
the gluteal region is recommended, 
procedures can be carried out using 
draping if this is required in order 
to gain patient cooperation. 
Chaperones or same sex 
practitioners are recommended in 
the case of female patients.
Unfortunately, this novel 
paradigm may meet with closed 
minds and automatic rejection. Patience 
and understanding of “closed” mindsets is 
essential in order to advance this new discovery in a 
way commensurate with its importance.
*See for example http://dermnetnz.org/
pathology/blaschko-lines.html.
My initial email and abstract were constructed 
to include appeals to authority, hints of con-
spiracy theories, and “scienciness,” but with an 
absence of evidence or plausibility. I received this 
from the organisers on 26 July 2010.
Dear Prof. John C. McLachlan,
You have sent a proposal to the The (sic) Jerusalem 
International Conference on Integrative Medicine. 
We are happy to inform you that the Scientific 
Committee has reached its decision and that your 
paper has been accepted and you will be able to 
present your lecture. The time frame will be 15-20 
minutes. Considering the tight schedule, I will 
appreciate if you’ll confirm your participation in 
the convention.
Unfortunately, I did not believe that I wished 
to carry the joke so far as to actually attend, 
although part of me was tempted.
I fully accept that this is just one instance, 
relating to a particular conference. And con-
ference abstracts are refereed less stringently 
than full papers. But I also believe that the idea 
I proposed was intrinsically and self evidently 
ridiculous. Whereas Sokal’s hoax parodied the 
incomprehensibility and reductio ad absurdum 
of some proponents of cultural studies’ approach 
to natural sciences, this particular hoax parodied 
the absurdity and credulity of so called integra-
tive medicine. I do not believe that rational medi-
cine could have been fooled with something so 
intrinsically ridiculous as in this case. Minimum 
standards of common sense should, I think, have 
led to a polite but firm rejection—or at least fur-
ther inquiry. Alternative medicine is not noted for 
rigorous inquiry, for research designed to prove 
the null hypothesis, but rather accepts notions 
on face value. Therefore a face value test is fair.
I did also, to be honest, feel a little uncomfort-
able about it. There was an element of deception 
involved, and academic intercourse generally 
relies, to some degree, on good faith. I sent off 
the abstract in a spirit of fun, but then hesitated 
about making it public. I did decline the invita-
tion (though I have never been to Jerusalem, and 
would have enjoyed the trip) but I didn’t want to 
cause harms by taking up a conference slot. But 
in the end, just as so called gentle teasing may 
reveal structures to the anatomist, so a different 
kind of gentle teasing may reveal something to 
the philosopher, and may promote an element of 
self awareness in proponents of alternative medi-
cine, no matter what grand title it is disguised 
under. It provides, at the least, an opportunity for 
reflective practice, which I hope proves of some 
benefit to us all.
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Society, and have written an award winning text 
book on medical embryology. Recently, as a result 
of my developmental studies on human embryos, 
I have discovered a new version of reflexology, 
which identifies a homunculus represented in 
the human body, over the area of the buttocks. 
The homunculus is inverted, such that the head is 
represented in the inferior position, the left buttock 
corresponds to the right hand side of the body, 
and the lateral aspect is represented medially. As 
with reflexology, the “map” responds to needling, 
as in acupuncture, and to gentle suction, such as 
cupping. In my studies, responses are stronger and 
of more therapeutic value than those of auricular or 
conventional reflexology. In some cases, the map 
can be used for diagnostic purposes.
Although I resisted the temptation to draw 
an analogy with the mappings of phrenology, I 
still had it in mind, and the reference to gentle 
suction might have been taken by a sceptical 
reader to refer to the idea of kissing the point of 
credulity. 
The organisers replied on the same day.
Dear Prof. McLachlan
I thank you for your interesting and enriching mail. 
In order to bring the proposal to the Scientific 
Committee I would appreciate it if you could send 
me an Abstract of your proposed lecture. And a 
short C.V.
Yours Sincerely
[name redacted]
The Jerusalem International Conference on 
Integrative Medicine
I replied on the following day: 
ABSTRACT
Intensive study of the development of early human 
embryos indicates that there is a reflexology style 
homunculus represented in the human body, 
over the area of the buttocks. This homunculus 
corresponds to areas of clonal expansion 
(“Blaschko lines*”), in which compartments of 
the body have clear ontological relationships 
with corresponding areas of the posterior flanks. 
The homunculus is inverted, such that the head 
is represented in the inferior position, the left 
buttock corresponds to the right hand side of 
the body, and the lateral aspect is represented 
medially. The Blaschko lines mediate energy flows 
to parent areas, and lead to significant responses 
to appropriate stimuli. As with reflexology, the 
“map” responds to needling, as in acupuncture, 
and to gentle suction, such as cupping. Responses 
are stronger and of more therapeutic value than 
those of auricular or conventional reflexology. In 
some cases, the map can be used for diagnostic 
purposes. In both therapeutic and diagnostic 
interventions, a full case history must be taken, 
bmj.com/archive
 ЖChristmas 2009: Secret remedies: 
100 years on (BMJ 2009; 339:b5432)
TH
E 
NA
TU
RA
L H
IS
TO
RY
 M
US
EU
M
, L
O
ND
O
N
READING BETWEEN THE LINES
1314	 	 	 BMJ | 18-25 DECEMBER 2010 | VOLUME 341
E
very doctor has an ethical duty 
to keep up to date. Is this just get­
ting more difficult or has it already 
become impossible? Since Alvin 
T offler coined the phrase “inform­
ation overload” in 1970,1 the growth of sci­
entific and medical information has been 
inexorable. There are now 25 400 journals in 
science, technology, and medicine, and their 
number is increasing by 3.5% a year2; in 2009, 
they published 1.5 million articles.2 PubMed 
now cites more than 20 million papers.
One response of the medical profession to the 
increasing scientific basis and clinical capacity of 
medicine has been to increase subspecialisation. 
This may restrict the breadth of knowledge of the 
ultra specialist, but can such subspecialists main­
tain their depth of expertise? Taking one medical 
subspecialty as an example, we have examined 
the gap between information and human capac­
ity, and we explore the implications for any doctor 
who wants to practise evidence based medicine.
Methods
We searched the database of the US National 
Library of Medicine (PubMed) on 12 September 
2010 for references relating to diagnostic imaging 
in cardiology. The table shows the search terms 
used.
Citations with any reference to echocardio­
graphy (the mainstay of diagnosis) were searched 
first, and then the strategy was narrowed to 
echocardiography as a main topic and restricted 
to controlled clinical trials (strategies 1­4; table). 
It is recommended that junior colleagues should 
be trained in several imaging modalities,3 and so 
we performed further searches for the concept 
of “multimodality imaging” in cardiology. This 
included single photon emission computed tomo­
graphy (SPECT), positron emission tomography 
(PET), magnetic resonance imaging, computed 
tomography (CT), and coronary arteriography, as 
well as cardiovascular ultrasound (strategies 5­6, 
table).
All searches were performed for each year from 
1966 (the year before ultrasonics was introduced 
as a search term in 
PubMed; echocardi­
ography was added in 
1973) to 2009. Trends 
in papers on echocar­
diography were mod­
elled; a good fit—from 
a cubic model contain­
ing time, the square 
of time, and the cube 
of time—was used to 
predict the numbers of 
publications to the end 
of 2010 and annually 
to 2015.
Results
The table  shows the publications retrieved by each 
search, along with totals for the last full calendar 
year. Figures 1 and 2 show annual totals to 2009 
and predictions from 2010 until 2015.
Search 5 without the cardiovascular system 
gave 700 011 citations. A search for “diagnostic 
imaging” [Mesh] and “cardiovascular system” 
[Mesh] gave 195 106 papers, or 159 661 if lim­
ited to human studies, core clinical journals, and 
Medline.
To estimate the time that it might take a new 
entrant to the subspecialty to read all the previ­
ous literature, we assumed that he or she could 
read five papers an hour (one every 10 minutes, 
followed by a break of 10 minutes) for eight hours 
a day, five days a week, and 50 weeks a year; this 
gives a capacity of 10 000 papers in one year. 
Reading all papers referring to echocardiography 
(search 1) would take 11 years and 124 days, by 
which time at least 82 142 more papers would have 
been added, accounting for another eight years 
and 78 days. Before our recruit could catch up 
and start to read new manuscripts published the 
same day, he or she would—if still alive and even 
remotely interested—
have read 408 049 
papers and devoted (or 
served a sentence of) 
40 years and 295 days. 
On the positive side, 
our recruit would fin­
ish just in time to retire.
Reading only the 
major studies would 
need more than four 
years for strategy 3 and 
more than five years 
for strategy 6. Alterna­
tively, if only one year 
was allocated for study, 
then for strategy 3 our 
recruit would need to read 95 papers every single 
day. If our recruit kept to the European Working 
Time Directive, he or she would have to read 138 
papers a day, or for strategy 6, 162 papers a day at 
a rate of one every three minutes.
To keep up to date, the cardiac imaging special­
ist needs to read 30 papers a week on echocardio­
graphy or 43 a week on multimodality imaging. If 
limited to one paper every working day (estimated 
total 250 a year), then the chance that he or she 
will read any particular paper is 1 in 8.9. The 
chance that a colleague on the opposite side of the 
world will read that same paper in the same year 
is 1 in 79. If each reads a random selection of 250 
papers a year, then the median number that both 
will read can be estimated at 28 (range 16­40) or 
1.3% of the total.
A search strategy restricted to evidence on out­
comes would not work for this subspecialty. The 
Search	strategies	for	identifying	articles	on	diagnostic	imaging	in	cardiology
Strategy Question
Total	no	of	papers	from	1966	to	
September	2010
Papers	published	
in	2009
1 All papers that include any reference to echocardiography 113 976 7207
2 All papers cited with echocardiography as medical subject heading 84 689 4672
3 All papers with echocardiography as a main topic 34 577 1558
4 Papers with echocardiography as a main topic, restricted to human controlled trials 457 23
5 All papers referring to the cardiovascular system and any one of multiple imaging modalities cited as a medical subject 
heading; referred to in text as any “multimodality imaging”
109 604 7083
6 All papers referring to the cardiovascular system or diagnosis of cardiovascular disease and any one of multiple 
imaging modalities, if cited as a main topic and limited to humans; referred to in text as major “multimodality imaging”
40 496 2226
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Fig 1 | Trends in numbers of papers listed each 
year in PubMed, according to search strategies 1-4 
in table. The numbers to the right of the vertical line, 
after 2009, are projected totals. MeSH=medical 
subject heading, Majr=as a main topic; 
CTs=controlled clinical trials
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average number of controlled clinical trials that 
were published during the decade 2000­9 (search 
4) was 26 each year. This number is not increas­
ing, and it represents only 2% of the publications 
with echocardiography as a main topic (search 3) 
or 0.5% of all papers referring to echocardio graphy 
(search 1) during the same period.
Discussion
The gap between what we can learn and what is 
known is increasing all the time. We now know 
less and less about more and more, so being 
expert means knowing and publicly acknowl­
edging the limits of your ignorance. Our analysis 
of one subspecialty showed no evidence whatso­
ever that the problem is abating, and remarkably 
similar patterns were reported recently for clinical 
t rials and systematic reviews.4 Keeping up with 
the literature has already become a Sisyphean 
task. We are even engulfed by information over­
load about “information overload”5; searching 
this term on Google gives about 980 000 hits.
We did assume that all papers have equal 
value, which is clearly untrue, but we did not 
allow any time in our calculations for obtaining 
papers, and we ignored the projected increases. 
Impact factors are concentrated in a few jour­
nals,6 and citation errors are common,7 so try­
ing to use either to select what to read would be 
unreliable for a topic such as medical imaging. 
Misconceptions are promulgated when authors 
do not check primary sources,8  9 and even when 
findings are contradicted by randomised control­
led trials.10 Systematic reviews are not all being 
kept up to date.11 Thus, delegating the selection of 
reading material to others might be unrewarding.
If anything, we probably underestimated calls 
on the doctor’s time 
for reading. Accurate 
diag nosis is a prerequi­
site for evidence based 
medicine, but experts 
in multimodality imag­
ing should also know 
something about clini­
cal and other aspects of 
their specialty.
Faced by the deluge 
of data, it is tempting to 
be nihilistic. After all, 
being ignorant of 100% 
of the literature in your field is not significantly 
different from being ignorant of “only” 98%. On 
the other hand, reading even 2% is more than 
reading nothing at all. The average specialist 
reads 322 papers a year,14 and a few brave, excep­
tional, and overcommitted people might accept 
the challenge of reading more. For most ordinary 
mortals, this is impossible, and for clinicians who 
are not also researchers it may no longer be sensi­
ble. Reading the literature has become a collective 
rather than an individual pursuit, and each of us 
must change our behaviour to reflect this.
Medical students and doctors in training can 
be taught to search databases effectively.15 Doc­
tors can use new information technologies to 
gain prompt and efficient access via the internet 
to the most relevant new data for their specialty.16 
The Cochrane Collaboration is admirable, but its 
programme of systematic reviews is not compre­
hensive, so all academic institutions and medi­
cal professional associations should contribute to 
collective efforts to summarise medical evidence 
and build trustworthy, interactive repositories 
of knowledge on the internet. Authors of clini­
cal guidelines have a particular responsibility to 
ensure that their recommendations are based on 
rigorous and re­testable meta­analyses of ran­
domised controlled 
trials, health technol­
ogy assessments, and 
systematic reviews. 
Appropriate resources 
must be allocated 
for researchers and 
experienced senior 
colleagues to dedicate 
time to these activi­
ties. More could also 
be done to develop 
decision support 
tools.17
In fields such as diagnostic imaging the 
plethora of publications hides the fact that we 
still lack sufficient evidence for rational practice. 
The small proportion of papers that were cited 
as controlled clinical trials (search 4) reinforces 
this notion. The best way to assess any diagnostic 
strategy is a controlled trial in which investiga­
tors randomise patients to diagnostic strategies 
and measure mortality, morbidity, and quality of 
life,18 but only 2.4% of diagnostic recommenda­
tions in the guidelines from the American Heart 
Association and the American College of Cardio­
logy are supported by this level of evidence.19
It is time for the profession to be more imagina­
tive. How can we reduce the number and increase 
the quality of publications?20 Can we remove the 
responsibility of all researchers to publish all 
their results? Could they contribute instead to 
wikis? Can we construct open access internet 
resources that allow data mining? Only initiatives 
such as these will overcome our worrying find­
ing that colleagues in the same medical discipline 
may inhabit intellectual worlds with little overlap. 
Happy reading!
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f you leaf through the June 2000 issue of 
the  British Journal of Cardiology you will see 
advertisements for Zocor, Xenical, and Cozaar 
before you reach a brand name that does not 
contain a prominent x or z (and that brand 
is Viagra). In an issue of  Hospital Doctor from 
the same month (22 June), adverts for Celebrex, 
Topamax, Flomax, Vioxx, Zispin, Zyprexa, 
Oxis, Efexor, and Fosamax outnumber those 
for brands not containing letters from the tail 
end of the alphabet. Examination of the  British 
National Formulary ( BNF ) from 1986 to 2004 
confi rms that z and x suddenly achieved remark-
able and previously unexplained popularity in 
the branding of drugs. 
 Of 1436 products added to the  BNF between 
1986 and 2005, more than a fi fth had names 
that began with z or x or contained a prominent 
x or z within them. In 1986, only 19 branded 
drugs began with one of these letters. Over the 
next two decades, the number of brands begin-
ning with a z increased by more than 400% (to 
63) and those beginning with an x increased by 
130% (to 16). In the same period, the overall 
content of the  BNF grew by only 80%. 
 Why did these letters suddenly become so 
attractive to companies trying to persuade doc-
tors to prescribe their drugs? In linguistics, the 
“zuh” sound is described as a voiced fricative. 
The “fricative” element refers to the fact that air-
fl ow directed over the tongue becomes turbulent 
when passing the sharp edges of the teeth, while 
the “voiced” aspect refl ects the vibration of the 
vocal cords. But there is nothing magical in the 
sound itself. One suggestion for the popularity of 
z is that it works well in the Middle East, which 
was becoming an increasingly important mar-
ket for drug com-
panies. This 
has a superfi cial plausibility: think of how 
Arab scientists launched astronomy 
with the terms zenith and azi-
muth. X, though representing 
the unknown for centuries, 
has been famously associated 
with medical advance since 
x rays. So this too would 
have appeal. 
 More likely, though, is that use of these letters 
relates to the imperative to make a brand name 
highly visible in a crowd. Refl ecting their infre-
quent occurrence in English words, x and z count 
for 8 and 10 points in Scrabble, the highest val-
ues (along with j and q) in the game. So names 
that contain them are likely to seem special and 
be memorable. “If you meet them in running 
text, they stand out,” is the way one industry 
insider explained. Generally, they are also easy 
to pronounce. 
 That is an old insight in the wider fi eld of mar-
keting. But in pharmaceuticals z did not really 
take oﬀ  as a brand initial until after 1996, with 
the number of drugs beginning with the letter ris-
ing steeply from 29 to 51 in 2000 (fi gure). And the 
widespread use of x (often also pronounced as 
“zuh”) is later still. Something additional started 
the bandwagon rolling. 
 Z and x spell Zuxess 
 Whatever the initial thinking that lay behind 
the use of the letter, the people responsible for 
marketing drugs spotted in the 1990s that an 
unusually large number of z brands had already 
achieved blockbuster status or were well on the 
way towards it. 
 Both Wellcome and Glaxo—then unrelated 
companies—showed an early liking for z and 
enjoyed conspicuous success. Wellcome had 
introduced Zyloric for gout in 1966 and Glaxo the 
intravenous antibiotic Zinacef in 1978. But it was 
in 1981 that both companies hit the jackpot with 
Wellcome’s launch of the antiherpes drug Zovirax 
and Glaxo’s launch of the H 2  receptor antagonist 
Zantac. In 1985, Zovirax became the world’s fi rst 
billion dollar drug; and Zantac was the world’s 
best selling drug by 1986. 1   2 In its fi rst 20 years, it 
was used to treat more than 200 million people. 3 
 The antihistamine Zirtek and the fi rst agonist 
of luteinising hormone releasing hormone Zola-
dex (both introduced in 1989), the antibiotic 
Zithromax (1991), and the proton pump inhibi-
tor Zoton (1994) all became highly successful; 
and Prozac (1987) made such an impression 
that its name branded a generation. In 2003, 
three of the world’s top 10 drugs (each grossing 
between 3 and 10 billion dollars annually) were 
Zocor, Zyprexa, and Zoloft. 4 Also among the top 
 A dose by any other name would 
not sell as sweet 
Inventors of drug names suddenly stood the alphabet on its head. Why did z and x become 
so attractive in the attempt to infl uence prescribers, asks Rob Stepney
 Generic names of drugs listed in the article  
Brand name Generic name
Zocor Simvastatin
Xenical Orlistat
Cozaar Losartan
Viagra Sildenafil
Celebrex Celecoxib
Topamax Topiramate
Flomax Tamsulosin
Vioxx Rofecoxib
Zispin Mirtazapine
Zyprexa Olanzapine
Oxis Formoterol
Efexor Venlafaxine
Fosamax Alendronic acid
Zyloric Allopurinol
Zinacef Cefuroxime
Zovirax Aciclovir
Zantac Ranitidine
Zirtek Cetirizine
Zoladex Goserelin
Zithromax Azithromycin
Zoton Lansoprazole
Prozac Fluoxetine
Zoloft Sertraline
Nexium Esomeprazole
Plavix Clopidogrel
Xanax Alprazolam
Xylocard Lidocaine
Xyloproct Lidocaine
Xalacom Latanoprost
Xenazine Tetrabenazine
Xyzal Levocetirizine
Xeloda Capecitabine
Xatral Alfuzosin
Zestril Lisinopril
Innovace Enalapril
Tritace Ramipril
Pulmicort Budesonide
Flixonase Fluticasone
Taxol Paclitaxel
Oncovin Vincristine
Herceptin Trastuzumab
Erbitux Cetuximab
Aprovel Irbesartan
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ten drugs that year were two with the X factor: 
Nexium and Plavix. 
 The widespread use of x at the start of a brand 
is a more recent ploy in drug marketing, seem-
ingly designed to achieve the sound of a z while 
looking diﬀ erent. In the 1985  BNF there are a few 
(notably Xanax, Xylocard, and Xyloproct). The 
big year for brand introductions with this feature 
did not come until 2002, but by 2005 there were 
more than a dozen including Xalacom, Xenazine, 
Xyzal (successor to Zirtek), Xeloda, and Xatral. 
 People who work in branding speak of it as a 
means of making a product more than it actu-
ally is. In many areas, this is achieved by add-
ing persuasive emotional (and some would say 
irrational) content. If you buy a car named after 
an animal famed for its exhilarating speed and 
elegance, that is what you associate with the vehi-
cle. But in the tightly regulated world of pharma-
ceuticals, drug names are supposed to be devoid 
of what the Medicines Control Agency used to call 
“unsubstantiable benefi cial” connotations. 
 Certain drug names have always alluded 
helpfully to the chemical class of the 
agent (as in Innovace, Tritace), its target 
organ (Pulmicort, Flixonase), the plant 
species from which the prototype drugs 
were derived (Taxol, Oncovin) or the drug’s 
molecular target (Herceptin, Erbitux). Otherwise, 
when they are sticking to the rules, those invent-
ing brand names for drugs have little scope to 
play with anything but the sound of letters, and 
to some extent the appearance of the word. This 
is presumably why we have the odd repetitions 
seen in Vioxx and Cozaar) If any alphabetical 
quirk seems to be working well, there must be a 
strong temptation to follow suit. 
 Sometimes, though, the rules get bent or 
broken. Aprovel manages to convey the idea of 
endorsement and Celebrex and Zestril a clear 
joie de vivre. Indeed, the contrasting stories of 
the two brands of lisinopril, both launched in the 
late 1980s, would make an interesting case study. 
ICI Pharmaceuticals called its lisinopril Zestril. 
Its competitors marketed the same molecule as 
Carace. Whereas Zestril became one of the medi-
cal world’s most successful brands, Carace sank 
pretty much without trace. Was the diﬀ erence due 
to the z, the zest, or both? 
 Product naming, of course, is an art that 
extends across all commercial activity; and z 
and x have played an important role elsewhere. 
Of the 10 cars currently listed as fastest in the 
world (all capable of 0-60 mph in under four 
seconds), four—including the Ferrari Enzo and 
the Jaguar XJ220—have a z or x in their names. 5 
For some brands, the prominence of a key letter 
is fortuitous: Zanussi, the white goods manufac-
turer, apparently derived its name from the early 
20th century blacksmith and stove manufacturer 
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 A Christmas 
tree cataract 
 A 73 year old woman referred for cataract surgery had on examination a right Christmas tree cataract (fi g 1A). Highly 
refl ective, iridescent, polychromatic crystals were noted within the lens. Their colours varied according to the angle of the 
incident light, (fi g 1B, C). It has been postulated that Christmas tree cataracts result from the accelerated breakdown of 
membrane associated proteins. The peptides and amino acids accumulate in the lumen of the reticular meshwork, and 
cystine is concentrated beyond the level of crystallisation, giving rise to growing crystals. 
 Ebube E  Obi  specialist trainee, ophthalmology , Gartnavel General Hospital, Glasgow G12 0YN, UK  e.obi@nhs.net 
 C  Weir  consultant ophthalmologist , Gartnavel General Hospital, Glasgow G12 0YN, UK 
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Antonio Zanussi. But there are many examples 
of brand name coinage that are as contrived as 
those used to market drugs and precede them. For 
the best part of a century, marketing has gone for 
certain arbitrary syllables like “ex”, “ax” or “ox.” 
These are stuck on to a meaningful word, as in 
Timex, Artex, or Tampax, or a meaningful word 
misspelt, as in Kleenex (introduced in 1924). 
Xerox, which became a trademark in 1948 (50 
years before the double x stratagem became 
popular for drugs) is an acknowledged classic. 
 That said, the use of x and z in drug brands 
suddenly became extraordinarily prevalent. I sug-
gest that this phenomenon arose because of the 
fast rate at which new products were being intro-
duced, the fact that the diﬀ erence between many 
“me too” drugs was more apparent than real, the 
immense rewards that were seen to accrue from 
innovative marketing, and the fact that the ploys 
available for use in the naming of drugs are so 
restricted. 
 I thank the staff of the BMA library for their help in enabling 
me to consult copies of the  British National Formulary from 
1985 to 2005. 
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A 
Little Red Hen lived in 
a university hospital 
where she took care 
of the sick animals in 
the different wards. 
She did this under the oversee-
ing eye of her wise and learned 
mentors. There was the Cow, who 
had a degree from a prestigious 
overseas university. There was 
the Pig, who had led mergers of 
several high standing hospitals 
in the country. And there was the 
Sheep, who had an outstanding 
treatment record with almost no 
animal morbidity and mortality.
One day the Little Red Hen 
thought: “Why don’t I see if I 
can use my scarce free hours 
at the end of the day and make 
an excellent pie. Not only will 
this pie add to the gastronomic 
knowledge, it could be that the 
sick animals will benefit from 
this pie in the long run.”
So the Little Red Hen ran her 
idea past her mentors.
“Great idea,” said the Cow. “I 
will supply the milk and the but-
ter. Of course, I would like a piece of the pie 
when it is baked.”
“Excellent,” said the Pig. “I happen to know 
the editor of a prestigious cook book. I expect 
a piece of the pie once it is finished.”
“Good thinking,” said the Sheep. “My labo-
ratory will provide the necessary utensils. Just 
make sure I get a share of the pie.”
The Little Red Hen wasted no time. Every 
day, after taking care of the sick animals she 
spent the last few hours of daylight planning 
the pie. She took classes in pie making, wrote 
pie making protocols, and even obtained 
approval from the institutional pie review 
board. And after a few months, all prepara-
tions were in place.
The Little Red Hen first went to the Cow and 
asked for the milk and the butter. “I have the 
milk and the butter for you. However, I heard 
that the Sheep will also have a part of the pie. I 
want you to make sure that my piece of the pie 
is larger than that of the Sheep.”
The Little Red Hen continued to the Pig. 
“Hold on,” said the Pig. “I have submitted a 
grant application for possibly an even bigger 
pie, so I cannot actively co-operate any longer 
on the current pie. However, if you do bake it, 
don’t forget to give me a piece.”
The Little Red Hen then visited the Sheep. 
The Sheep was abroad for a conference on 
a nimal wellbeing with an extended post- 
conference tour, and his laboratory had received 
no instructions to provide any ut ensils.
The Little Red Hen went to work. She tested 
her own recipes, made do with her limited 
utensils, and fluttered between different 
departments to keep everybody satisfied. 
Finally, after many long hours and many failed 
pies, an acceptable pie came out of the oven.
Overjoyed, the L ittle Red Hen called together 
her mentors to share the news.
“Welcome every one,” said 
the Cow. “I would like to present 
the outstanding result of our co-
operation.” She then took half of 
the pie and left the room. The Pig 
was next. “Excellent work, Little 
Red Hen.” He cut himself a size-
able piece of the pie and left the 
room. Then the Sheep stepped 
forward. “What a feat of culinary 
craftsmanship did we achieve! 
Congratulations on your first 
pie.” He cut a small piece of the 
pie, and took the rest.
The Little Red Hen sat in the 
conference room and stared 
at the small piece of pie that 
remained. Although happy to 
have baked her first pie and to 
have contributed to the gastro-
nomic knowledge, she was left 
with an inexplicable feeling 
of disappointment. It did take 
quite some time before the Lit-
tle Red Hen attempted to bake 
another pie.
Disclaimer: This tale is based upon 
coffee table stories and a compilation of 
reported experiences in the academic 
hospital at no specific place. Any names, characters, places, 
and incidents are either the product of the tale or are used 
fictitiously. Any resemblance to actual events or locales or 
persons, living or dead, is entirely coincidental.
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Pie sharing in complex clinical  
collaborations: a piece of cake?
The Little Red Hen learns some important new lessons in  
K T Buddingh’s cautionary, but entirely fictitious tale
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